**Graybug Vision (NASDAQ:GRAY) Announces Public Offering Priced at $3.75 per Share**

Graybug Vision, trading on the NASDAQ under the symbol GRAY, disclosed the pricing details of its public offering in a recent 8-K filing with the United States Securities and Exchange Commission. The company revealed that it entered into an underwriting agreement with JonesTrading Institutional Services LLC on October 30, 2024, for the issuance and sale of 2,720,000 shares of common stock at a price of $3.75 per share. The offering is expected to generate gross proceeds totaling $10,200,000 before deducting underwriting discounts, commissions, and other estimated expenses.

The offering, done under an effective registration statement on Form S-3, is set to close on November 1, 2024, subject to customary closing conditions. Additionally, the company granted the underwriter a 30-day option to purchase up to 408,000 additional shares of common stock at the offering price.

The Underwriting Agreement includes standard representations, warranties, and agreements, along with termination provisions, indemnification obligations, and other related terms. Representations and covenants in the agreement were tailored for specific dates and parties involved, covering liabilities under the Securities Act of 1933.

In a separate action on the same day, October 30, 2024, Graybug Vision issued a press release disclosing the pricing of the offering. The company emphasized that certain statements within the press release are forward-looking and cautioned about potential risks and uncertainties related to the offering, market conditions, and broader macroeconomic events such as geopolitical tensions.

Graybug Vision provided the opinion of Cooley LLP regarding the legality of the offering in an exhibit attached to the filing. The company expressed that it does not intend to update forward-looking statements beyond the initial disclosure, except as required by law.

Investors interested in obtaining additional details about the offering can refer to the filed documents on the Securities and Exchange Commission’s website. The company’s Contact for Investors and Media is Argot Partners, reachable at [email protected].

The offering, discussed in the filing, outlines Graybug Vision’s strategic financial move as it continues to navigate the investment landscape and pursue opportunities for growth in the industry.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Graybug Vision’s 8K filing here.

About Graybug Vision

Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.